Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group

Ketty Peris, Maria Concetta Romano, Vasiliki Nikolaou, Vincent Sibaud, Davide Fattore, Ariadna Ortiz-Brugués, Damien Giacchero, Julia Riganti, Konstantinos Lallas, Dimitra Voudouri, Aimilios Lallas, Gabriella Fabbrocini, Elisabeth Lazaridou, Cristina Carrera, Maria Carmela Annunziata, Angela Patri, Dimitrios Rigopoulos, Alexander J. Stratigos, Zoe Apalla

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Background: Immune checkpoint inhibitor (ICI)–mediated psoriasis poses significant diagnostic and therapeutic challenges. Objective: To report data on ICI-mediated psoriasis, emerging from the largest cohort to date, to our knowledge, and to propose a step-by-step management algorithm. Methods: The medical records of all patients with ICI-mediated psoriasis were retrospectively reviewed across 9 institutions. Results: We included a cohort of 115 individuals. Grade 1, 2, and 3 disease severity was reported in 60 of 105 (57.1%, 10 missing data), 34 of 105 (32.4%), and 11 of 105 (10.5%), respectively. The ratio between exacerbation and de novo cases was 1:4.3. The most common systemic therapy was acitretin (23 patients, 20.1%), followed by systemic steroids (8 patients, 7%), apremilast (7 patients, 6.1%), methotrexate (5 patients, 4.3%) and biologics (4 patients, 3.6%). Overall, 29 of 112 patients (25.9%) interrupted and 20 of 111 (18%) permanently discontinued ICIs because of psoriasis. Body surface area of greater than 10% at baseline had a 3.6 increased risk for ICI treatment modification (odds ratio, 3.64; 95% confidence interval, 1.27-10.45; P =.03) and a 6.4 increased risk for permanent discontinuation (odds ratio, 6.41; 95% confidence interval, 2.40-17.11; P <.001). Guttate psoriasis and grade 2 or 3 disease were significant positive predictors for antitumor response of ICI, whereas pruritus was a negative predictor. Limitations: Retrospective design. Conclusion: Acitretin, apremilast, and methotrexate are safe and effective modalities for ICI-mediated psoriasis. In most cases, ICI can be completed unhindered. A therapeutic algorithm is proposed.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJournal of the American Academy of Dermatology
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • adverse events
  • immune checkpoint inhibitors
  • immunotherapy
  • nivolumab
  • pembrolizumab
  • psoriasis
  • skin toxicity

Fingerprint

Entra nei temi di ricerca di 'Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group'. Insieme formano una fingerprint unica.

Cita questo